MktsMarkets

Cullinan Therapeutics, Inc.
NASDAQ: CGEMKey statistics
CGEM News
Stories mentioning CGEM from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 42,123 | 42,945 | 41,968 | 61,030 | 41,459 | 40,492 | 35,506 | 36,259 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 53,697 | 55,259 | 55,595 | 75,798 | 54,996 | 55,048 | 48,855 | 50,027 |
| Operating Income (Loss) | (53,697) | (55,259) | (55,595) | (75,798) | (54,996) | (55,048) | (48,855) | (50,027) |
| Interest Income | 4,098 | 4,615 | 5,093 | 5,924 | 6,580 | 7,512 | 8,384 | 8,071 |
| Interest Expense | ||||||||
| Other Expense | (62.00) | (69.00) | (108.00) | (181.00) | (85.00) | 6.00 | (89.00) | (72.00) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (50,713) | (50,610) | (70,055) | (48,501) | (47,647) | (40,560) | (42,028) | |
| Earnings Per Share (Basic) | (0.69) | (0.75) | ||||||
| Earnings Per Share (Diluted) | (0.69) | (0.75) | ||||||
| Weighted Average Shares Outstanding (Basic) | 58,337 | 55,052 | ||||||
| Weighted Average Shares Outstanding (Diluted) | 58,337 | 55,052 | ||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CGEM
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a stock listed on the Nasdaq Stock Market under the ticker symbol CGEM. It last traded at $12.93 (Oct 16, 2026, 4:00 PM ET), down 7.6% on the day. That gives Cullinan Therapeutics a market capitalisation of $832.1M.
Over the past 52 weeks CGEM has traded between $6.73 and $23.19.
For the quarter ended Dec 31, 2025 it reported a net loss of $50.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Dec 31, 2025 | — | -$50.7M |
| Sep 30, 2025 | — | -$50.6M |
| Jun 30, 2025 | — | -$70.1M |
| Mar 31, 2025 | — | -$48.5M |
From Cullinan Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…